Patient characteristics
| Patient characteristics . | All patients, n (%) . | Molecular DLBCL subtypes by biomarker analysis on part B,*n (% of group) . | P . | |
|---|---|---|---|---|
| GCB DLBCL . | ABC DLBCL . | |||
| Total patients | 49 (100%) | 15 (56%) | 12 (44%) | |
| Median age, y (range) | 54 (18-78) | 57 (39-70) | 58 (21-73) | .75 |
| Stage | ||||
| III/IV | 42 (86%) | 12 (80%) | 12 (100%) | .23 |
| Lactate dehydrogenase | ||||
| > Normal | 28 (57%) | 12 (80%) | 7 (58%) | .39 |
| Performance status | ||||
| ECOG ≥ 2 | 9 (18%) | 4 (27%) | 2 (17%) | .66 |
| International Prognostic Index | ||||
| High intermediate/high risk | 24 (49%) | 7 (47%) | 7 (58%) | .70 |
| Histology | ||||
| DLBCL (de novo)† | 34 (69%) | 15 (100%) | 12 (100%) | |
| PMBL | 4 (8%) | 0 | 0 | |
| Transformed | 7 (14%) | 0 | 0 | |
| Other‡ | 4 (8%) | 0 | 0 | |
| Prior treatment | ||||
| Median CT regimens (range) | 2 (1-7) | 2 (1-5) | 2 (1-7) | .78 |
| Median months last therapy (range) | 4 (1-69) | 4 (1-37) | 3 (1-18) | .84 |
| Refractory to last CT regimen§ | 21 (43%) | 5 (33%) | 3 (25%) | .70 |
| Prior BMT | 10 (20%) | 3 (20%) | 4 (33%) | .66 |
| Patient characteristics . | All patients, n (%) . | Molecular DLBCL subtypes by biomarker analysis on part B,*n (% of group) . | P . | |
|---|---|---|---|---|
| GCB DLBCL . | ABC DLBCL . | |||
| Total patients | 49 (100%) | 15 (56%) | 12 (44%) | |
| Median age, y (range) | 54 (18-78) | 57 (39-70) | 58 (21-73) | .75 |
| Stage | ||||
| III/IV | 42 (86%) | 12 (80%) | 12 (100%) | .23 |
| Lactate dehydrogenase | ||||
| > Normal | 28 (57%) | 12 (80%) | 7 (58%) | .39 |
| Performance status | ||||
| ECOG ≥ 2 | 9 (18%) | 4 (27%) | 2 (17%) | .66 |
| International Prognostic Index | ||||
| High intermediate/high risk | 24 (49%) | 7 (47%) | 7 (58%) | .70 |
| Histology | ||||
| DLBCL (de novo)† | 34 (69%) | 15 (100%) | 12 (100%) | |
| PMBL | 4 (8%) | 0 | 0 | |
| Transformed | 7 (14%) | 0 | 0 | |
| Other‡ | 4 (8%) | 0 | 0 | |
| Prior treatment | ||||
| Median CT regimens (range) | 2 (1-7) | 2 (1-5) | 2 (1-7) | .78 |
| Median months last therapy (range) | 4 (1-69) | 4 (1-37) | 3 (1-18) | .84 |
| Refractory to last CT regimen§ | 21 (43%) | 5 (33%) | 3 (25%) | .70 |
| Prior BMT | 10 (20%) | 3 (20%) | 4 (33%) | .66 |
DLBCL indicates diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; PMBL, primary mediastinal B-cell lymphoma; CT, chemotherapy; and BMT, autologous or allogeneic bone marrow/stem cell transplant.
Molecular subtypes determined by microarray and/or immunohistochemistry.
Excludes PMBL subtype.
‡Two DLBCL by histology were reclassified as Burkitt lymphoma by microarray in this group.
No response to last combination chemotherapy regimen. P values for binary variables were calculated using a Fisher exact test, and numeric values (age, regimen number, and time from last treatment) were calculated using a Wilcoxon rank test.